🇺🇸 FDA

Company profile · Sponsor

Ensysce

Ensysce Biosciences

ENSC · NYSE pharma LA JOLLA, CA, USA
Pipeline
6
Drugs
0
Patents
2

Quick answer

Ensysce (ENSC) is a pharma company. headquartered in LA JOLLA, CA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 2 patents to this profile..

Company facts

Ticker ENSC
Exchange NYSE
Company type pharma
Headquarters LA JOLLA, CA, USA
SEC CIK 0001716947

Pipeline (6)

Search pipeline →

  1. PF614 capsule

    Ensysce

    Postoperative Pain, Acute

    phase 3 small molecule active

    1 trial

  2. PF614

    Ensysce

    Acute Pain

    phase 2 small molecule completed

    1 trial

  3. PF614

    Ensysce

    Healthy

    phase 1 small molecule completed

    1 trial

  4. PF614

    Ensysce

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. PF614

    Ensysce

    Recreational Drug Use

    phase 1 small molecule completed

    2 trials

  6. PF614 capsule

    Ensysce

    Pharmacokinetics

    phase 1 small molecule active

    1 trial

Patents (2)

Search patents →

  1. US 12384744

    Enzyme-cleavable methadone prodrugs and methods of use thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8772258

    Single walled carbon nanotube/sirna complexes and methods related thereto

    Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Ensysce?

Ensysce (ENSC) is a pharma company. headquartered in LA JOLLA, CA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 2 patents to this profile..

What pipeline programs does Ensysce sponsor?

We track 6 ClinicalTrials.gov-linked programs for Ensysce, including PF614 capsule and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Ensysce company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.